Member Info for ImaWinner

Good morning.

After watching the downs and ups of CIR for a very long time, I have been finally persuaded to fill my boots this morning.

RA1 post is highly pertinent and the confirms the current under stress and under valuation of CIR.

Being familiar with the respiratory space and the fundamentals of the typical commercial deal structures that underpin assets such as those purchased from AZ, and the NioX test ricing and reimbursement, I fully expect CIR to deliver a robust 2019 full year performance with a concomitant uplift in share price.

In many ways there is a lot of similarity to the historic Skyepharma (SKP) share price journey, and they ended up with a very positive exit to Vectura and a decent premium.

We will have to wait and see if any suitors emerge for CIR in the medium term, but dont discount VEC thinking about it now their CEO (JWL) has departed. I doubt very much that any Big Pharma will consider CIR.

CIR has many things VEC doesnt, and a similar shareholder register. Hikma, Cipla, Lupin, amd Mylan, would also be possibly buyers.